Ionis Gets FDA Approval for Rare Disease Drug Tryngolza

Shares of Ionis Pharmaceuticals (IONS) rose nearly 5% in after-market trading on Thursday after the FDA approved its RNA-targeted therapy, olezarsen, in adults with familial chylomicronemia syndrome (FCS). The drug will be marketed under the trade name Tryngolza.The FDA’s nod to Tryngolza makes it the first approved treatment for FCS in the country. The drug’s commercial launch is part of management's broad strategy to deliver a steady flow of wholly-owned medicines to patients. Besides being Ionis’ first w ...